Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations
Diffuse Large B Cell Lymphoma|Lymphoma
DRUG: Pembrolizumab
Overall response rate (ORR) to pembrolizumab treatment compared to historical controls., 2 years
Duration of response (DOR) to pembrolizumab treatment, 2 years|Progression-free survival (PFS), 2 years|Overall survival (OS), 5 years
A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations